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Introduction {#sec1}
============

The key to HIV-1 vaccine development is the induction of broadly neutralizing antibodies (bnAbs). The currently known classes of bnAbs target six functional regions on the envelope glycoprotein encompassing the V2 apex, the V3 glycan site, the CD4 binding site, the gp120-gp41 interface region, the gp120 silent face, and the membrane proximal external region (MPER) of Env gp41 ([@bib48], [@bib84]). MPER-specific bnAbs 4E10, 10E8, DH511, and VRC42 target the same helical linear epitope, which precedes the transmembrane (TM) region ([@bib10], [@bib33], [@bib46], [@bib95], [@bib97]), and neutralizes more than 90% of multiclade strains ([@bib46], [@bib84]).

A hallmark of MPER bnAbs are long, heavy-chain CDR3 (HCDR3) loops carrying hydrophobic residues at their tips, whose interaction with membrane is required for neutralization ([@bib3], [@bib41], [@bib66], [@bib78]). MPER bnAbs show various degrees of autoreactivity linked to immune tolerance mechanisms ([@bib15], [@bib23]) that could impair MPER bnAb development. BnAbs 4E10 and VRC42.01 show the most significant non-specific interaction with lipids and membrane ([@bib2], [@bib46]), while 10E8 and DH511 lineage bnAbs lack important non-specific membrane binding ([@bib33], [@bib46], [@bib95]), indicating that non-specific membrane autoreactivity is not a prerequisite of bnAbs targeting MPER. However, specific interaction with membrane is important and structures of 4E10 and 10E8 revealed lipid binding of both bnAbs ([@bib36], [@bib37]). Based on these structures, models of the Fab-MPER-membrane interface have been generated and have shown that the MPER epitope helix lies nearly perpendicular to the membrane ([@bib36], [@bib37], [@bib75]). Although MPER bnAbs 4E10, 10E8, and DH511 recognize the same epitope, their approach angles vary ([@bib95]). In contrast, VRC42.04 is a close variant of 4E10 that recognizes the same epitope with the same approach angle as 4E10. Interestingly, the latter bnAbs have been independently generated in clade B-and clade CRF016AE-infected patients ([@bib46], [@bib97]).

MPER epitopes are likely only poorly accessible on native Env trimers, and full epitope accessibility requires at least some degree of receptor/co-receptor-binding-induced conformational changes in Env ([@bib12], [@bib51], [@bib72]). Consequently, MPER bnAbs bind with high affinity to the fusion intermediate conformation of gp41 ([@bib14], [@bib28], [@bib49]). This conformation forms during the receptor-binding-induced transitions from native Env ([@bib67]) to the postfusion conformation ([@bib9]), thereby facilitating exposure of the linear MPER sequence motif in a membrane context. This transient conformation is suitable for bipartite anti-MPER bnAb binding of the MPER and membrane.

Dependent on the patient cohort investigated, MPER-specific Abs are either present in a large number of patient sera with broad neutralizing activity ([@bib22], [@bib33], [@bib58]) or are reported to be rare ([@bib50], [@bib71]). Importantly, their presence increases the potency and breadth of the sera substantially in comparison to V2 apex bnAbs ([@bib38]). Furthermore, antibody cocktails including MPER antibodies are more potent ([@bib45]), and *in vitro* the presence of 10E8 in a 4-antibody cocktail reduced significantly the amount of incomplete neutralization ([@bib91]). Finally, both 4E10 and 10E8 protect animals from SHIV infection by passive immunization ([@bib31]) ([@bib68]).

Here, we have isolated a broad and potent anti-MPER neutralizing Ab, LN01, derived from lymph-node germinal center B cells of an elite controller infected with a clade B strain. This antibody uses a heavy-chain germline V gene and thus extends the B cell repertoire for the induction of MPER bnAbs. We have determined the reactivity of the unmutated common ancestor (UCA) and the role of the extensive load of somatic mutations for neutralization. We show that in addition to the MPER epitope, LN01 binding requires part of the TM for interaction. Structural studies have revealed the role of the TM and that of specific lipid-binding pockets. It is noteworthy that MPER forms a continuous helix with the complete gp41 TM region. In synergy with molecular dynamics simulation, we propose a model of LN01 interaction with its monomeric epitope and with the membrane, revealing important implications for gp41 immunogen design targeting the LN01 lineage.

Results {#sec2}
=======

LN01 Isolation and Characterization {#sec2.1}
-----------------------------------

Among a cohort of chronically HIV-1-infected patients, naïve to antiretroviral therapy, we identified a patient (SA003) who showed high level of serum bnAbs, as assessed on a panel of 9 HIV-1 pseudoviruses (PVs) from the Global Panel of HIV-1 Env reference strains ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Of note, SA003 donor is an elite controller with viremia \<50 HIV-1 RNA copies per mL of plasma (infected with clade B HIV-1). From patient SA003, we isolated lymph node mononuclear cells (LNMC) and sorted IgG memory B cells (CD19^+^IgA^−^IgM^−^CD27^+^CD38^−^) and IgG germinal center (GC) B cells (CD19^+^IgA^−^IgM^−^CD27^+^CD38^+^). The two B cell subsets were immortalized with Epstein-Barr virus (EBV) in the presence of anti-B-cell-receptor polyclonal antibodies and cultured for 14 days on a monolayer of mesenchymal stromal cells (MSCs) together with a cocktail of stimuli composed of IL2, IL21, IL6, and the TLR-9 agonist CpG-2006. The supernatants of B cell cultures were screened for their ability to neutralize 2 HIV-1 PVs from the Global Panel, BJOX2000 (clade CFR07) and CE1176 (clade C). One B cell supernatant from the IgG GC B cell library showed a high percentage of neutralization against both PVs tested (\>70% for BJOX2000 and \>90% for CE1176) ([Figure S1](#mmc1){ref-type="supplementary-material"}B). The VH and VL regions of the monoclonal antibody produced by this B cell clone were sequenced and expressed as recombinant IgG1 monoclonal antibody, hereafter referred to as LN01.

The sequence analysis revealed that LN01 was originally an IgG3 antibody encoding the IGHV4-39 and IGKV1-39 VH and VK germline genes. Two common features of HIV-1 bnAbs were also found in LN01 mAb: high frequency of somatic mutations in the heavy and light chain variable regions compared to the germline sequence (28% and 27%, respectively) and a long HCDR3 loop made of 20 amino acids ([Figure 1](#fig1){ref-type="fig"}A). The alignment of LN01 amino acid sequences with the unmutated common ancestor (UCA) sequences showed a high degree of mutations in HCDR1, framework 2 (FR-H2), FR-H4, LCDR1, LCDR2, and FR-L4 ([Figure 1](#fig1){ref-type="fig"}B).Figure 1Analysis of LN01 mAb Sequence and Neutralization(A) Analysis of LN01 sequences showing the inferred germline genes and alleles encoding the variable region of the heavy and light chains, the amino acid length of the CDR3 regions and the mutation frequency of the variable regions of the light and heavy chains (aa, amino acid).(B) Alignment of the amino acid sequences of the variable regions of LN01 wild-type and LN01 UCA. The CDRs regions are highlighted in gray.(C) LN01 IgG1 activity was tested *in vitro* in neutralization assay using TZM-bl cells. Different concentrations of the antibody were tested against nine pseudoviruses (PVs) of the Global Panel plus a control PV (SVA-MLV). Shown on y axes is the % of neutralization and the standard deviation (SD) calculated on quadruplicates.(D) Schematic of LN01 unmutated common ancestor (UCA) and variants created for investigation of the neutralization requirements of LN01 germlined variants. Light gray areas represent sequence from UCA; dark gray regions are from the somatic, mature antibody. Wild-type, somatically mutated heavy (sH), or somatically mutated light (sL) chains; gH or gL, germline V-gene revertants of sH or sL in which HCDR3 or LCDR3 are mature; gH-FR or gL-FR, germline V-gene revertants of sH or sL in which HCDRs or LCDRs are mature.(E) Box-and-whisker plots showing the neutralizing activity of LN01 germline variants against a panel of eight PVs of the Global Panel as measured using a neutralization assay on TZM-bl cells.

The neutralizing activity of recombinant LN01 IgG1 mAb was initially tested against a small panel of 9 HIV-1 PVs (and a control PV, SVA-MLV). LN01 was found to neutralize 8 PVs with a median IC~50~ value of 0.57 μg/mL (ranging between 0.03 μg/mL of TRO.11 and 1.61 μg/mL of BJOX2000) ([Figure 1](#fig1){ref-type="fig"}C). We also checked the neutralizing activity of LN01 mAb expressed in the IgG3 and Fab formats. Of note, both IgG3 and Fab formats showed the same neutralizing activity as compared with LN01 IgG1 ([Figure S2](#mmc1){ref-type="supplementary-material"}).

To further characterize the LN01 mAb activity we determined whether FcγRI expressed on target cells could augment the potency of Ab-mediated neutralization of HIV-1 PVs, an effect that was previously described to occur with gp41 MPER-specific neutralizing Abs and not with gp120-specific mAbs such as b12 and 2G12 ([@bib69]). Hence, we tested side by side the LN01 IgG1 neutralizing activity on parental TZM-bl cells versus TZM-bl expressing FcγRI in parallel with two anti-MPER bnAbs, 10E8 and 4E10. Differences in neutralization potencies of ≥3-log between parental target cells and FcγRI cells were observed for 10E8 and 4E10, as well as for LN01 ([Figure S3](#mmc1){ref-type="supplementary-material"}). This improved potency may result from a kinetic advantage unique to antibodies whose epitopes are difficult to access or exposed for only a short time, such as the MPER displayed on intermediate conformations of the Env protein during an early stage of fusion. Taken together, these results show that LN01 is a bnAb with high breadth and potency against a multi-clade HIV-1 PVs panel.

Neutralization by LN01 Is Dependent on Somatic Mutations {#sec2.2}
--------------------------------------------------------

To investigate the role of somatic mutations on the neutralizing activity of LN01, we generated nine LN01 variants with FR and CDR regions completely reverted to the germline in VH and VK and compared their neutralizing activity to that of the fully mutated LN01 mAb ([Figures 1](#fig1){ref-type="fig"}D and 1E). The germlining of all somatic mutations in the heavy chain (UCA VH variant) completely abolished LN01-neutralizing activity against the HIV-1 PVs tested, regardless of which light-chain variants were used (UCA/UCA, UCA/gL, and UCA/sL variants). Similarly, the germlining of all somatic mutations in the light chain (UCA VL variant) also abolished LN01 neutralizing activity, independently of which heavy-chain variants were used (sH/UCA, gH/UCA, UCA/UCA variants).

However, when the mature light chain is paired to the heavy chain completely reverted to the germline except for HCDR3 (gH/sL variant), LN01-neutralizing activity is impaired but not abolished. Of note, when the mature heavy chain is paired to the light chain in which all the FRs are reverted to the germline and the CDRs are mature (sH/gL-FR), the LN01 neutralizing activity is comparable to that of the fully mutated Ab (sH/sL) ([Figure 1](#fig1){ref-type="fig"}E). These results show that with respect to the light chain only the somatic mutations in the CDRs (8 mutations in a total of 29 mutations) are required for LN01 activity. Thus, this raises the question whether other somatic mutations can be as well reverted to germline while maintaining the LN01 neutralizing activity.

Analysis of LN01 Autoreactivity {#sec2.3}
-------------------------------

A common feature of several HIV-1 bnAbs, e.g. 2F5, 4E10, and 10E8, is that they cross-react with self-antigens. To evaluate LN01 mAb autoreactivity, we tested its binding to HEp-2 epithelial cells and to cardiolipin. LN01 showed a low binding to HEp-2 cells at the highest concentration tested comparable to the staining with 10E8 but significantly lower than 4E10 ([Figure 2](#fig2){ref-type="fig"}A). No binding was observed to cardiolipin ([Figure 2](#fig2){ref-type="fig"}B). To further characterize the LN01 bnAb, we performed the pharmacokinetic study in huFcRn transgenic mice. Following intravenous administration, the LN01 serum concentration declined over the 2 weeks of observation with kinetics similar to those of a control mAb specific for an irrelevant antigen and superior to those of the clinical stage mAb palivizumab ([Figure 2](#fig2){ref-type="fig"}C). These results show that LN01, based on the preliminary assessment, seems to be non-autoreactive and to have a favorable pharmacokinetic profile. More in-depth analysis is needed to confirm the safety profile of LN01.Figure 2Analysis of LN01 Autoreactivity(A) Immunofluorescence on Hep-2 cells. BnAbs LN01, 4E10, and 10E8 as well as positive and negative controls provided by the diagnostic kit were tested at 50 μg/mL.(B) ELISA to measure the binding to the self-antigen cardiolipin. Assay performed according to manufacturer instructions. Shown are OD values of duplicates at 405 nm.(C) Pharmacokinetic analysis performed in huFcRn transgenic mice (Tg276, Jackson Laboratory). LN01, palivizumab and a control mAb specific for an irrelevant antigen were administered i.v. at 10 mg/kg (n = 5). The concentration of human mAbs in plasma ± standard deviation (SD) was determined at multiple time points using a total human IgG ELISA, as described in [STAR Methods](#sec4){ref-type="sec"}.

LN01 Neutralization Breadth, Potency, and Effector Function {#sec2.4}
-----------------------------------------------------------

Since the LN01 mAb showed high breadth and potency against a small panel of HIV-1 PVs, it was then tested against an 118-isolate Env-PVs panel in parallel with bnAb 10E8. LN01 neutralized 92% of the tested PVs compared to 95% for 10E8; the median IC~50~ were 1.1 and 0.8 μg/mL for LN01 and 10E8, respectively. When the IC~80~ values are considered, LN01 and 10E8 neutralized 83% and 85% of the tested PVs with a median of 7.4 and 6.1 μg/mL for LN01 and 10E8, respectively ([Figure 3](#fig3){ref-type="fig"}A). Of note, the neutralizing activity of LN01 was not skewed to specific clades, albeit it seems to be less effective on clade A (the SA003 patient was infected by a clade B HIV-1) ([Table S1](#mmc1){ref-type="supplementary-material"}). Thus, LN01 mAb mediates broad and potent neutralization against a large panel of HIV-1 viruses comparable to bnAb 10E8 ([Figure 3](#fig3){ref-type="fig"}B).Figure 3LN01 Neutralization Breadth, Potency, and Effector Function Killing of HIV-1-Infected Lymphocytes(A) The neutralizing activity of LN01 IgG1 tested against a cross-clade panel of 118 HIV-1 PVs. The IC50 (top panel) and IC80 (bottom panel) expressed in mg/ml were determined in TZM-bl-cell-based micro-neutralization assay as described in [STAR Methods](#sec4){ref-type="sec"}.(B) Neutralization breadth-potency curves for LN01 and 10E8, with breadth shown as percentage of PVs neutralized at each IC50 (top panel) or IC80 (bottom panel) cutoff (25 μg/mL for LN01 and 10 μg/mL for 10E8).(C) ADCC killing of HIV-1 infected lymphocytes performed with bnAbs at 15 μg/mL on CEM-NKR-CCR5 cells infected with NLAD8, YU2, CH058, or CH077 HIV-1 strains. ADCC was calculated as the disappearance of Gag+ cells with or without antibodies (n = 6--10), with each dot representing an individual donor of primary NK cell. ADCC responses of each tested antibody were compared to that of the isotype control mGO53 in the Wilcoxon test (^∗^p \< 0.05).(D) CDC-mediated cell killing performed with bnAbs at 15 μg/mL incubated with a Raji-YU2 Env cell line in the presence of normal human serum from six individual donors or heat-inactivated human serum. The mGO53 antibody was used as a negative control in (C) and (D).

The targeted killing of HIV-1 infected lymphocytes is an effector function held by some but not all bnAbs. Antibody-dependent cellular cytotoxicity (ADCC) is mediated through the binding of the Fc portion of the antibody to Fc receptors that are expressed on effector cells including natural killer (NK) cells. In complement-dependent cytotoxicity (CDC), antibody binding to the target cell induces cell lysis that is triggered by the binding of C1q subunits to the Fc antibody region. For *in vitro* ADCC evaluations, CEM-NKR-CCR5 CD4 T cells infected with one of four HIV-1 viral strains were cultured with primary NK cells in the presence or absence of different antibodies ([Figure 3](#fig3){ref-type="fig"}C). ADCC activities of IgG1 and IgG3 versions of LN01 were compared to that of bnAbs 10E8 and 4E10. BnAbs 3BNC117, 10--1074, PGT128, PGT151 (all IgG1) and the isotype control mG053 were used as controls. One lab-adapted (NLAD8) and three primary strains of HIV-1 (YU2, CH058, and CH077) were tested. In this assay, LN01 IgG1 displays significant ADCC against the four HIV-1 strains tested at levels that are comparable to control bnAbs. LN01 IgG3 showed a reduced response. 10E8 displayed ADCC against 1 out of 4 strains and 4E10 showed no response ([Figure 3](#fig3){ref-type="fig"}C). CDC-mediated cell lysis induced through bnAbs was evaluated using Raji cells engineered to stably express cell surface levels of HIV-1 YU2 envelope. Following the incubation of cells with human serum and antibodies, the appearance of dead cells was monitored by flow cytometry with heat-inactivated human serum used as negative control. LN01 IgG1 and IgG3 antibodies both exhibited specific CDC-mediated killing of the envelope positive cells at equivalent levels observed for 10E8, while 4E10 showed substantially reduced CDC activity ([Figure 3](#fig3){ref-type="fig"}D).

LN01 Epitope Specificity and Binding {#sec2.5}
------------------------------------

The results described above suggested that LN01 could target the MPER of HIV-1 Env. To address this hypothesis, we used a panel of HIV-2/HIV-1 chimeric PVs containing various segments of the HIV-1 MPER replacing the parental HIV-2/7312A sequences ([@bib88]). Importantly, IgG1 LN01 antibody did not neutralize the parental HIV-2 7312A strain. IgG1 LN01 antibody was found to potently neutralize the chimeric virus 7312A.C4 in which six residues from HIV-1 were replaced in the HIV-2 MPER region (**[LAS]{.ul}**W**[VK]{.ul}**YI**[Q]{.ul}** replaced by **[ITK]{.ul}**W**LW**YI**K**) but not the chimeric virus 7312A.C6 in which only three residues in the same region were replaced (**[LA]{.ul}**SW**[V]{.ul}**KYIQ was replaced by **IT**SW**I**KYIQ) ([Figure 4](#fig4){ref-type="fig"}A). A similar finding was observed with the chimeric virus 7312A.C1C where the same six mutations of 7312A.C4 were combined with additional seven mutations in the N-terminal region of MPER. These results indicate that residues in the C-terminal region of the gp41 MPER (in particular L679, W680, and K683) are involved in IgG1 LN01 antibody binding and neutralization activity, thus indicating that LN01 is a MPER-specific bnAb.Figure 4Relevant Residues on HIV-1 PVs for LN01 Binding(A) HIV-2 chimera containing HIV-1 MPER region and parental HIV-2 were used to determined the binding of recombinant LN01. In the table are shown the IC50 (mg/mL) calculated based on the neutralization assay with TZM-bl cells (middle column), and the different mutations in the sequence carried by MPER of each chimeras (right column).(B) The activities of LN01, 10E8, and 4E10 mAbs against several MPER mutants of the COT6.15 virus were assessed. Shown are the IC50 values expressed in μg/mL.

To better define the specificity of LN01 we used a peptide microarray formed by 1423 15-mer peptides, overlapping by 12 amino acids, that cover the full length of the consensus HIV-1 Env gp160 sequences for clades A, B, C, D, group M, CRF01_AE, and CRF02_AG. LN01 was tested in parallel with a control antibody called 7B2 (that is specific for the immunodominant region of gp41) for binding to the peptide microarray. Of note, IgG1 LN01 antibody did not react with any of the peptides in this library, while 7B2 strongly reacted with 190--195 peptides that spanned the gp41 immunodominant region ([Figure S4](#mmc1){ref-type="supplementary-material"}A). In addition, LN01 did not interact with a 28-amino-acid peptide spanning the entire MPER region ([Figure S4](#mmc1){ref-type="supplementary-material"}B).

To further refine the epitope mapping, we tested LN01 and two other MPER-specific mAbs, 10E8 and 4E10, against a panel of COT6.15 viruses (clade C) encoding MPER mutants ([@bib88]). LN01 neutralizing activity was reduced by \>8-fold against viruses with the mutants F673A, D674A and D674S (both F673 and D674 are shared in HIV-2), while only marginally reduced against the W672A mutant ([Figure 4](#fig4){ref-type="fig"}B). Of note, 10E8 shared with LN01 the reduced activity against the F673A, D674A, and D674S mutants, but its activity was reduced by 2-log against the W672A mutant, indicating that LN01 and 10E8 share a similar interaction with F673 and D674 but are likely to interact differently with W672.

Because LN01 did not interact with a MPER-peptide-containing residues 671--683, longer MPER-containing peptides, MPER-TM1 (residues 671--689 including seven TM residues) and MPER-TM2 (residues 630--711, containing the complete TM region) ([Figure S5](#mmc1){ref-type="supplementary-material"}A) were tested in binding studies. MPER-TM2, solubilized in a buffer containing β-D-octyl glucoside (β-OG), forms trimers ([Figure S5](#mmc1){ref-type="supplementary-material"}B) but does not interact with LN01. However, when solubilized in a buffer containing Fos-Choline-12, MPER-TM2 is monomeric and forms a complex with LN01 Fabs ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Binding kinetics were analyzed both in β-OG and in Fos-Choline-12-containing buffers by surface plasmon resonance (SPR) and compared to 10E8 interaction with MPER-TM1 and MPER-TM2. From this analysis, K~d~s were measured to be 160.8 nM for LN01 binding to MPER-TM1 in β-OG and 170.0 nM for interaction with MPER-TM1 in Fos-Choline-12, showing similar binding in both detergents. The interaction with MPER-TM2 is tighter, resulting in a K~d~ of 13.0 nM, underlining a role for the complete TM region. Binding of 10E8 yielded K~d~s of 62.0 and 36.9 nM for the interaction with MPER-TM1 and again a slightly higher affinity of 24.2 nM for the interaction with MPER-TM2 ([Figure S5](#mmc1){ref-type="supplementary-material"}D). We conclude that the LN01 epitope extends from MPER into the TM region.

LN01 Structures in Complex with MPER-TM {#sec2.6}
---------------------------------------

Crystal structures of LN01 were determined in complex with MPER-TM1, in complex with MPER-TM1 and phosphatidylserine (06:0 PS), and in complex with MPER-TM2 to resolutions of 3.2 Å, 3.1 Å, and 3.9 Å, respectively ([Table S2](#mmc1){ref-type="supplementary-material"}). Two identical complexes of LN01/MPER-TM1 were present in the asymmetric unit. MPER-TM1 residues 671--689 adopt a slightly bent helical conformation in complex with LN01 ([Figure 5](#fig5){ref-type="fig"}A). Main contacts are mediated by polar interactions, D674 to LCDR3 T94, N677 to LCDR3 H92, T676 to HCDR3 W100h, and K683 to the carbonyls of HCDR3 F100 and S100b ([Figure 5](#fig5){ref-type="fig"}B). Furthermore, gp41 F673 inserts into a hydrophobic pocket composed of HCDR3 W100h, HCDR1 Y35, and LCDR3 W96. In addition, numerous hydrophobic contacts include long-range interactions of HCDR3 residues, F100 and W100a, to gp41 I682, I686, and M687, thereby positioning the tip of HCDR3 close to TM residues ([Figure 5](#fig5){ref-type="fig"}B; [Table S3](#mmc1){ref-type="supplementary-material"}). The overall contact interface of the Fab and MPER-TM1 spans 683 Å^2^. The structure also reveals the presence of a Fos-Choline-12 detergent molecule ([Figure S6](#mmc1){ref-type="supplementary-material"}A); its phosphate group interacts with LCDR1 K31 and the cation of the choline inserts into a cation box ([@bib62], [@bib74]) made up of gp41 W680 and Y681 and LCDR1 Y32 and HCDR3 Y100g ([Figure 5](#fig5){ref-type="fig"}B). Co-crystallization of MPER-TM1-LN01 with 06:0 phosphatidylserine (PS) ([Figure S6](#mmc1){ref-type="supplementary-material"}B) revealed a network of polar interactions coordinating one PS molecule. HCDR3 S97 and HCDR2 Y52 hydrogen bond to the carbonyl of PS, HCDR1 D32 contacts the amide of PS, the amide of HCDR3 F100 hydrogen bonds to the phosphate group of PS, and HCDR3 W100a to the carbonyl of the acyl chain ([Figures 5](#fig5){ref-type="fig"}B and [S6](#mmc1){ref-type="supplementary-material"}B). This interaction network reveals how lipid interaction coordinates the HCDR3 extended conformation, allowing W100a immersion into the lipid bilayer. Notably, most residues coordinating epitope recognition, Fos-Choline-12, and PS interaction in LN01 are present in the LN01 UCA. Exceptions are LCDR1 K31 (Fos-Choline-12, phosphocholine head group), which itself is coordinated by LCDR2 Y52 ([Figure 5](#fig5){ref-type="fig"}B), LCDR3 H92 (contacting MPER), HCDR1 D32, and HCDR2 Y52 (contacting PS), as well as LCDR3 H92 (contacting gp41) ([Figures 1](#fig1){ref-type="fig"}B and [5](#fig5){ref-type="fig"}B). Furthermore, replacement of UCA HCDR3 G100c by wild-type (WT) HCDR3 T100c likely influences the HCDR3 loop conformation and its capacity to reach the lipid bilayer. Thus, LN01 UCA does not neutralize, mainly because it lacks specific lipid-binding sites.Figure 5Structure of LN01 in Complex with gp41 MPER-TM1 and with Lipid(A) Structure of the LN01-MPER-TM1 complex. LN01 is colored in yellow (light chain) and orange (heavy chain) and the N-acetyl-β-d-glucosamine (NAG) on Asn107 of the light chain is shown with spheres. Gp41 is colored in purple (MPER) and beige (TM). The same coloring was used in all figures.(B) Close up of the interactions with gp41 MPER, Fos-Choline-12, and PS revealing two lipid-binding sites on either side of the MPER helix. Fos-Choline-12, PS, and residues involved in polar contacts and important hydrophobic contacts are indicated and represented in sticks; hydrogen bond interactions are represented as dashed lines. The upper two panels show the interactions of LN01 with gp41 MPER from two different orientations. The lower left panel shows the interaction with Fos-Choline-12, a putative lipid-binding site accommodating phosphatidylcholine, and the lower right panel shows the hydrogen bond network that coordinates 06:0 PS forming a second lipid-binding pocket.

The neutralization analyses of LN01 variants having different heavy- and light-chain combinations ([Figures 1](#fig1){ref-type="fig"}D and [1](#fig1){ref-type="fig"}E) agree with the molecular details of LN01 epitope recognition. In order to define the importance of the interaction with the peptidic epitope, we analyzed the LN01 variants with respect to MPER-TM2 interaction ([Figure S7](#mmc1){ref-type="supplementary-material"}). Using bio-layer interferometry (BLI), WT (sH/sL) LN01 showed a K~D~ of 2.3 ± 0.01 nM, which is a factor of 5 higher than the K~D~ determined by SPR ([Figure S5](#mmc1){ref-type="supplementary-material"}D). LN01 sH/gL-FR ([Figure 1](#fig1){ref-type="fig"}E) binds the gp41 epitope with a K~D~ of 7.0 ± 0.03 nM indicating that light-chain framework mutations affect binding slightly while maintaining neutralization potency, except for strain 2570 ([Figure 1](#fig1){ref-type="fig"}E). LN01 gH/sL ([Figure 1](#fig1){ref-type="fig"}D) binds with a K~D~ of 6.2 ± 0.02 nM but shows no or lower potency in neutralization ([Figure 1](#fig1){ref-type="fig"}E) in agreement with the importance of HCDR1 D32 and HCDR2 Y52 for PS coordination ([Figure 5](#fig5){ref-type="fig"}B). LN01 gH/gL and LN01 gH/UCA ([Figure 1](#fig1){ref-type="fig"}D) both bind with low micromolar affinity (K~D~ = 1.4 ± 03 and 4.7 ± 1.7 μM) explaining their lack of neutralization. LN01 sH/gL has a 100-fold lower K~D~ of 453.3 ± 82 nM and exerts only some low potency neutralization ([Figure 1](#fig1){ref-type="fig"}E), which may be explained by the absence of the PS and Fos-Choline12-binding sites as well as the lower affinity due to potential long-range effects of light-chain CDR residues. LN01 UCA/UCA, UCA/sL, and UCA/gL ([Figure 1](#fig1){ref-type="fig"}D) showed no binding, in agreement with no neutralization ([Figure 1](#fig1){ref-type="fig"}E), highlighting the importance of HCDR3 interactions with gp41 ([Figure 5](#fig5){ref-type="fig"}B). This thus confirms the importance of both high-affinity gp41 peptide epitope interaction and lipid binding for neutralization.

The structure of LN01 in complex with MPER-TM2 containing the complete TM region reveals that MPER forms a continuous helix with the TM comprising residues 684--711 ([Figure 6](#fig6){ref-type="fig"}A). The asymmetric unit contained four complexes, two with a continuous straight MPER-TM helix and two with a 90° and 110° kink at the conserved Gly 691 in the middle of the TM region ([Figures 6](#fig6){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}E). LN01 interactions with MPER are the same in all four complexes and similar to the LN01-MPER-TM1 structures. Molecular dynamics (MD) simulations of the LN01-MPER-TM2 complex placed into a bilayer with a lipid composition analogous to that of the viral envelope ([@bib8]) revealed a 25° tilted orientation of the TM segment with respect to that of the bilayer ([Figure 6](#fig6){ref-type="fig"}C). This tilt orients the LN01 Fab on the membrane such that the HCDR3 dips into the bilayer and positions the lipid-binding sites to interact with lipid head groups ([Figure 6](#fig6){ref-type="fig"}D). Furthermore, the tilt angle of the TM allows residue K683 to interact with lipid head groups of one leaflet and R696 to contact head groups of the opposite leaflet; residues R707 and R709 terminating the TM helix interact as well with lipid head groups in the simulation ([Figure S6](#mmc1){ref-type="supplementary-material"}C).Figure 6Structure of LN01 in Complex with gp41 MPER-TM2 Reveals a Continuous Helix of MPER and TM(A) Structure of the LN01-MPER-TM2 complex with the TM in the straight conformation. Color coding is the same as in [Figure 5](#fig5){ref-type="fig"}. Gp41 MPER residues 650 to 670 are disordered in the LN01-MPER-TM2 structure.(B) Structure of the LN01-MPER-TM2 complex with the TM in the bent conformation.(C) Orientation of the LN01-MPER-TM2 complex in the lipid bilayer based on the MD simulation result (lipids are represented in sticks).(D) LN01-MPER-TM2 complex with modeled phosphatidylcholine and 06:0 PS (based on the LN01-MPER-TM1 structure) demonstrates that both lipids are well positioned to be part of the bilayer. Phosphatidylcholine and 06:0 PS are shown in spheres.(E) The angle of approach of MPER bnAbs. The upper panel shows the bnAbs LN01 (yellow), 10E8 (orange), 4E10 (blue), and DH511.1 (red), represented with a sphere at the center of the variable domain for each antibody.The middle panel shows their orientations upon recognition of the linear helical epitope as determined by Cα superposition of the MPER peptide of the four complexes (two side views and one top view looking down the helical axis of MPER).The lower panel shows the representation of the angle of approach of the different bnAbs on the MPER-TM domain inserted in the lipid bilayer (lipids and basic residues are shown as sticks). The trajectory between the center of each antibody and gp41 T676 is depicted by a straight line.

Although some of the LN01-interacting MPER-TM1 residues overlap with the contacts observed for bnAbs 10E8, 4E10, and DH511.1 (DH511.2) ([Figure S5](#mmc1){ref-type="supplementary-material"}E), all four antibodies approach the MPER epitope with different angles. Comparison of the approach angles, based on the orientation of the MPER-TM2 in the membrane as determined by MD simulation ([Figure 6](#fig6){ref-type="fig"}C), showed that Fabs 10E8, 4E10, and DH511.1 are rotated by 30°, 14°, and 34°, respectively, compared with the LN01 position ([Figure 6](#fig6){ref-type="fig"}E). Taken together, the different angles of approach of MPER bnAbs suggest that half of the MPER surface is immunologically silent and not accessible in any of the different conformational states of Env. In order to determine whether TM tilting in the membrane is induced by LN01 binding, we performed MD simulation to position the straight TM alone in the lipid bilayer. Furthermore, we included the bent TM conformation in the simulation to test its potential physiological relevance. Six 0.3-μs MD trajectories were generated, two of them starting from a straight TM helix, and four initiated with a bent TM helix. In the simulations starting from a straight TM helix, TM did not interconvert into a bent form ([Figures 7](#fig7){ref-type="fig"}A and 7B). Analysis of the trajectories indicates that the TM is steadily anchored to the lipid bilayer by interactions of K683 with the head groups of one leaflet, and residues R707/709 interacting with head groups of the other leaflet ([Figure 7](#fig7){ref-type="fig"}A) as shown in the LN01-MPER-TM2 simulation ([Figure S6](#mmc1){ref-type="supplementary-material"}C). Measuring the tilt of the α helix with respect to the membrane plane as a function of time revealed average tilt angles of 18° ± 5°, slightly smaller than the tilt angle imposed by the LN01 Fab interaction ([Figures 5](#fig5){ref-type="fig"}C and [S6](#mmc1){ref-type="supplementary-material"}C). This conformation indicates that the guanidine group of the strictly conserved central TM residue R696 can contact polar head groups ([Figures 7](#fig7){ref-type="fig"}A and [S6](#mmc1){ref-type="supplementary-material"}C). In contrast, simulations initiated with the bent TM revealed a propensity to interconvert toward a straight conformation. Out of four independent simulations, only one preserved a bent TM conformation, with a near 90° bending angle. In one simulation, the α helix rapidly retracted to a nearly straight form, while in the remaining two, the TM appears to navigate between the two conformations ([Figure 7](#fig7){ref-type="fig"}B). The central R696 can contact polar head groups in the bent conformation as well, and the anchoring residues at the membrane boundaries K683 and R707/709 squeeze the membrane, reducing its diameter locally ([Figure 7](#fig7){ref-type="fig"}C). The MD trajectories further suggest that the straight and the bent TM helices in a membrane are metastable states of the free-energy landscape, the straight conformation likely corresponding to a lower free-energy state than the bent form. To verify this hypothesis, the potential of mean force (PMF) underlying the transition between the two conformations was determined in an 11-μs multiple-walker adaptive-biasing-force (MW-ABF) simulation ([@bib19]). The one-dimensional free-energy profile features two minima separated by a 4.5 kcal/mol barrier, the straight and the bent conformations being 3.8 kcal/mol in favor of the former ([Figure 7](#fig7){ref-type="fig"}D). Thus, starting from a bent α helix, the free-energy barrier to overcome is only 0.7 kcal/mol. These observations indicate that depending on the initial conditions, the bent α helix can rapidly interconvert to a straight α helix. Conversely, at 310K (37°C), the straight α helix is very unlikely to bend to an elbow-shaped α helix, in line with our equilibrium brute-force MD simulations. We conclude that the straight TM region is the lowest energy state, which most likely represents the TM conformation present upon LN01 binding *in vivo*.Figure 7Molecular Dynamics Simulation of the Straight and Bent TM Conformations in a Lipid BilayerThe lipid bilayer is composed of POPC (turquoise), POPE (yellow-green), POPS (red), SSM (pink), and cholesterol (mauve). The lipid head groups are represented as van der Waals spheres of the corresponding colorcolour. The G residues of the α helix are highlighted as orange spheres.(A) MD simulation of the straight TM conformation reveals a tilt angle of 17°. The inset shows the complete assay, featuring water and the K^+^ (violet) and Cl^−^ (green) ions.(B) MD simulation of the bent TM conformation demonstrates that the bent form thins the membrane locally.(C) Time evolution of the bending angle, φ, formed by the long axes of the α-helical segments spanning residues I675 to M687 and I697 to N706 determined from six independent MD simulations. The inset of (C) depicts the time evolution of the tilt angle, θ, formed by the long axis of gp41 and the normal to the lipid bilayer.(D) Free-energy profile characterizing the transition between the straight (left minimum) and the bent (right minimum) conformations of gp41 in a membrane. The error bars correspond to the standard deviation measured from the eight walkers of the 11-μs MW-ABF simulation.

Discussion {#sec3}
==========

Here, we report the isolation as well as functional and structural characterization of a bnAb (LN01) isolated from lymph-node GC B cells of an elite controller. LN01, originally isolated as IgG3, uses IGHV4-39 and IGKV1-39 VH, and VK genes and neutralizes 92% of a 118-strain virus panel. We show that LN01 binds to the same gp41 MPER epitope as bnAbs 10E8, 4E10, DH511, and VRC42.04 ([@bib10], [@bib33], [@bib46], [@bib95]). However, LN01 interaction with the MPER epitope requires, in addition to MPER, amino acid residues in adjacent helical turns of the transmembrane region for interaction. Thus, at least one helical turn of the TM is an integral part of the LN01 epitope. Furthermore, the affinity of LN01 is 10 times higher when MPER is fused to the complete TM segment, which may provide a more stable TM structure. In line with a role of the TM for anti-MPER bnAb function, the affinity of 10E8 is 100 times higher when the MPER epitope is linked to part of the TM ([@bib75]).

The MPER epitope adopts the same helical structure in complex with 10E8, 4E10, DH511, VRC42, and LN01, although the contact residues differ because four of the five bnAbs approach the epitope from different angles. Together, they cover approximately 180° of the cylindrical MPER helix surface, which is inconsistent with a tight trimeric conformation. Indeed, a trimeric NMR model of MPER-TM indicates that the MPER epitope is not accessible in this conformation ([@bib21]). The cryoelectron microscopy (cryo-EM) structure of native Env in complex with PGT151 suggests that glycans N88 and N625 sterically hinder 10E8 binding to native Env trimers. Thus, in order to interact with native Env, 10E8 interaction requires lifting the trimer off the membrane surface, resulting in a conformation similar to the one induced by CD4 splaying MPER-TM apart ([@bib32], [@bib51]). Although these early conformational states of Env may provide initial binding, the binding affinity of 10E8 or other MPER antibodies to such an early conformational intermediate has not been investigated. The real target of bnAbs targeting MPER is most likely the gp41 fusion intermediate conformation ([@bib28], [@bib49]), whereas anti-MPER bnAbs prevent refolding into the fusion-active conformation ([@bib94]). This is also in agreement with the long mean half-life of neutralization ([@bib95]) linked to the prolonged MPER epitope exposure ([@bib81]) and in line with the increased neutralization potencies observed between parental cells and FcγRI cells as reported here.

Most MPER antibodies except VRC42 ([@bib46]) have been isolated as the IgG3 subclass, whose more flexible hinge region may favour MPER epitope recognition, although no differences in neutralization or CDC activity were observed between LN01 IgG1 and IgG3 subclasses. In contrast, LN01 IgG1 showed a trend toward improved ADCC mediated killing of HIV-1 infected lymphocytes compared to the IgG3. These potential differences between the LN01 antibody subclasses will require further ADCC investigation with a concentration response analysis. Interestingly, using four different strains of HIV-1, LN01 showed a higher ADCC activity than 10E8 and 4E10, the latter being negative in ADCC as reported previously ([@bib7]).

We further show that LN01 binds lipids similar to 4E10 and 10E8 ([@bib36], [@bib37]), which is likely to be a general feature of MPER bnAbs. The long HCDR3 with hydrophobic residues at its tip, which are essential for neutralization ([@bib3], [@bib14], [@bib41], [@bib54], [@bib66], [@bib78]), is another common feature of MPER bnAbs. Our MD simulations reveal that LN01 bound to MPER-TM is positioned such that HCDR3 can insert into the membrane, thereby interacting simultaneously with the first turn of the α-helical TM and lipids via at least two lipid-binding pockets. Thus, the membrane is part of a bipartite epitope, which increases the binding affinity ([@bib73]) and transforms MPER bnAbs into "conformational" Abs ([@bib64]). Although membrane interaction is essential for neutralization, LN01 autoreactivity with membranes in the absence of the gp41 epitope is below the detection level similar to that reported for 10E8 ([@bib33]) and VRC42.04 ([@bib46]) and thus is not as prominent as described for 4E10 ([@bib2], [@bib30]). Nevertheless, some autoreactivity such as specific lipid binding plays a role in the maturation of MPER bnAbs, in line with the suggestion that their generation requires the ability to overcome immune tolerance mechanisms ([@bib60]) by engaging antibody lineages induced by host proteins or microbiota ([@bib52], [@bib89]).

The germline VH and VL gene usage of MPER bnAbs shows similarities and differences. 10E8 and DH511 use the germline V gene IGHV3-15, and 4E10 and VRC42 employ IGHV1-69, while LN01 uses yet another one, IGHV4-39, hence expanding the VH repertoire of naïve B cells for MPER antibody generation. In contrast, the light-chain V gene usage of IGKV1-39 is shared between LN01 and the DH511, while 4E10 and VRC42 use IGKV3-20 and 10E8 IGLV3-19 ([@bib27], [@bib33], [@bib46], [@bib95]). This indicates that these five anti-MPER bnAbs, derived from four different patients, have found common and divergent solutions to the same problem, suggesting that successful targeting MPER might not be exceptional, in line with the presence of MPER-specific Abs in polyclonal sera ([@bib22], [@bib33]). The UCA version of LN01 does not neutralize PVs infection, in agreement with no detectable interaction with the gp41 MPER-TM2 epitope. Testing our different LN01 variants for epitope binding revealed that high-affinity peptide epitope binding, as well as the presence of both proposed lipid-binding sites, are important for LN01 neutralization and potency. Furthermore, many of the LN01 somatic mutations within the framework regions seem to be unimportant for neutralization. However, some long-range structural effects cannot be excluded, in agreement with findings that suggest that HIV-1 bnAbs require framework mutations for either increased flexibility and/or direct antigen contact ([@bib44]). In particular, our structural studies suggest that only five of the CDR somatic mutations are implicated in epitope and lipid binding. Similarly, a longitudinal study on the 4E10-related bnAb VRC42 suggests that it becomes broad with a low mutation rate ([@bib46]). Thus, further investigations will inform on the minimal requirement of mutations in light of improving LN01 developability properties.

The crystal structure of MPER-TM2 containing the complete TM region reveals a continuous helix of MPER and TM similar to the monomeric MPER-TM NMR structure ([@bib17]). Other structural models propose a hinge or helical bent connecting MPER and TM ([@bib5], [@bib47]), underlining some conformational flexibility within MPER. MD simulation placed the TM domain alone with an approximate 18° tilt angle in the membrane stabilized by the basic residues at both membrane boundaries. This conformation allows the central, strictly conserved R696 to interact with lipid head groups. Thus, R696 may be strictly conserved in order to position and/or stabilize the tilted TM during the conformational transitions of gp41, leading to membrane fusion ([@bib79]), which is consistent with the proposal that R696 is important for membrane-fusion efficiency ([@bib53]). We further observe a bent conformation of the TM region, which has no role in LN01 interaction. Although this may be a pure Fos-Choline-12 effect, bending occurs at Gly positions that are strictly conserved in HIV-1, HIV-2, and SIV TM sequences ([@bib13]). MD simulations confirmed that the TM region can navigate between a straight and bent conformation, both being metastable, although the straight form represents the lower free-energy state. Interestingly, the bent conformation compresses the membrane, and membrane thinning of SNARE TMs was proposed to lower the free energy of stalk formation by favoring the local concentration of highly bent stalk structures ([@bib83]) formed at early stages of the fusion process ([@bib16]). It is, therefore, tempting to speculate that a bent Env TM may have a similar role in membrane fusion.

In summary, the functional and structural data indicate that potential MPER immunogens must be linked to the native Env transmembrane region and incorporated in the membrane as the MPER epitope extends into the TM region, thereby generating the functional bipartite gp41 membrane epitope. Since the TM alone orients itself in the membrane with a tilt angle that is similar to the one induced or stabilized by LN01 interaction, MPER-TM inserted in the membrane may present the optimal immunogen. However, since MPER itself has some degree of conformational flexibility and may as well insert into the membrane when linked to the TM domain ([@bib5], [@bib47]), our structures indicate that stabilization of the continuous MPER-TM helix by chemical ([@bib6]) or other means could favor immunogenicity and thus B cell stimulation.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESourceIdentifier**Antibodies**PE-Cy7 Mouse Anti-Human CD19BD BiosciencesCat\#341113_clone SJ25-C1Alexa Fluor 488 goat anti-Human IgMInvitrogenCat\#A21215; RRID:[AB_2535800](nif-antibody:AB_2535800){#interref145}Goat anti-Human IgA FITCInvitrogenCat\#A18788; RRID:[AB_2535565](nif-antibody:AB_2535565){#interref150}Anti-Human CD3 PC5Beckman CoulterCat\#A07749Anti-Human CD38 APCBD PharmingenCat\#555462_clone HIT2 (RUO); RRID:[AB_398599](nif-antibody:AB_398599){#interref155}Anti-Human CD14 PC5Beckman CoulterCat\#A07765Anti Human CD27 BV650BioLegendCat\#302827_clone O323; RRID:AB_11124941AffiniPure F(ab')~2~ Fragment Goat Anti-Human IgA+IgG+IgM (H+L)Jackson ImmunoresearchCat\#109-006-064; RRID:[AB_2337548](nif-antibody:AB_2337548){#intref0010}AP-conjugated anti-human IgG secondary antibodySouthern BiotechCat\#2040-04; RRID: [AB_2795643](nif-antibody:AB_2795643){#interref160}10E8 recombinant mAbIRB and Pasteur; [@bib33]PMID:23151583; RRID:[AB_2491067](nif-antibody:AB_2491067){#interref165}HK20 recombinant mAbIRB;\
[@bib76]PMID:21124990; RRID:[AB_2491018](nif-antibody:AB_2491018){#interref175}4E10 recombinant mAbIRB and Pasteur; [@bib85]PMID:11788027; RRID:[AB_2491029](nif-antibody:AB_2491029){#interref170}LN01 Recombinant mAb and All Variantsthis paperN/AMouse Anti-HIV-1 Gag FITC (Clone KC57)Beckman CoulterCat\#6604665mGO53Dr. Hugo Mouquet, Institut Pasteur, Paris; [@bib93]PMID:129203033BNC117Produced by Dr. Hugo Mouquet; [@bib77]PMID: [21764753](pmid:21764753){#intref0015}; RRID:[AB_2491033](nif-antibody:AB_2491033){#interref180}10--1074Produced by Dr. Hugo Mouquet; [@bib63]PMID: [23115339](pmid:23115339){#intref0020}; RRID:[AB_2491062](nif-antibody:AB_2491062){#interref185}PGT128Produced by Dr. Hugo Mouquet; [@bib92]PMID:21849977; RRID:[AB_2491047](nif-antibody:AB_2491047){#interref190}PGT151Produced by Dr. Hugo Mouquet; [@bib25]PMID: [24768347](pmid:24768347){#intref0025}**Bacterial and Virus Strains**HIV-1 PV strain CE1176Fraunhofer Institute for Biomedical Engineering IBMTN/AHIV-1 PV strain BJOX2000Fraunhofer Institute for Biomedical Engineering IBMTN/AHIV-1 PV strain X1632Fraunhofer Institute for Biomedical Engineering IBMTN/AHIV-1 PV strain 25710Fraunhofer Institute for Biomedical Engineering IBMTN/AHIV-1 PV strain TRO.11Fraunhofer Institute for Biomedical Engineering IBMTN/AHIV-1 PV strain CH119Fraunhofer Institute for Biomedical Engineering IBMTN/AHIV-1 PV strain 246F3Fraunhofer Institute for Biomedical Engineering IBMTN/AHIV-1 PV strain CE0217Fraunhofer Institute for Biomedical Engineering IBMTN/AHIV-1 PV strain CNE55Fraunhofer Institute for Biomedical Engineering IBMTN/ASVA-MLV_control PVFraunhofer Institute for Biomedical Engineering IBMTN/AEpstein Barr VirusIRBN/ApCH058.c/2960NIH AIDS Reagent ProgramCat\#11856pCH077.t/2627NIH AIDS Reagent ProgramCat\#11742pNL(AD8)NIH AIDS Reagent ProgramCat\#11346pYU2NIH AIDS Reagent ProgramCat\#1350Standard panel of reference Env pseudoviruses[@bib34]Multiclade Reference Panel\
PMID:[27315479](pmid:27315479){#intref0030}OverExpress C41(DE3) chemically competent *E. coli* cellsSigma-AldrichCat\#CMC0017Ni-NTA AgaroseQiagenCat\#30210**Biological Samples**HIV-1 Infected ART Naïve Patient LNMCsHospital "Sacco" in Milan, ItalyN/AHuman serumEtablissement Français du SangN/A**Chemicals, Peptides, and Recombinant Proteins**28amino acids long peptide gp41 MPERPepscanN/AHuman recombinant IL-6BD PharmingenCat\#550071Human recombinant IL-21ImmunoToolsCat\#11340215Human recombinant IL-2IRBN/AMPER-TM1 PeptideSmart Bioscience[www.smart-bioscience.com](http://www.smart-bioscience.com){#intref0035}Fos-Choline-12anatraceCat\#F308n-Octyl-β-D-glucosid n-Octyl-β-D-GlucopyranosideanatraceCat\#O311PEG3350Sigma-AldrichCat\#88276PEG8000Sigma-AldrichCat\#89510HEPESSigma-AldrichCat\#H4034Ethylene glycolCarl RothCat\#6881.106:0 PSAvanti Polar LipidsCat\#840030**Critical Commercial Assays**ImmunoWELL cardiolipin (IgG) testGenBioCat\#3090Pierce Rapid Gold BCA Protein Assay kitThermo Fisher ScientificCat\#A53225PRNK cell isolation kitMiltenyi BiotecCat\#130-092-657LIVE/DEAD Fixable Aqua Dead Cell Stain KitInvitrogenCat\#L34965ANA HEp-2 Test SystemZeus ScientificCat\# FA2400EZ-LinkNHS-PEG4-Biotinylation KitThermo ScientificCat\#21455**Deposited Data**MPER-TM1-LN01 complexthis paper6SNCMPER-TM1-LN01-PS complexthis paper6SNDMPER-TM2-LN01 complexthis paper6SNE**Experimental Models: Cell Lines**TZM-bl cell lineNIH AIDS Reagent ProgramCat\#8129TZM-bl FcγRI cell lineNIH AIDS Reagent ProgramCat\#11798Expi293F cellsThermo Fisher ScientificCat\#A14527Mesenchimal stromal cells (MSC)IRBN/ACEM-NKR-CCR5NIH AIDS Reagent ProgramCat\# 4376RajiATCCCCL-86293T/17ATCCCat\# CRL-11268**Experimental Models: Organisms/Strains**Mouse: homozygous human FcRn (huFcRn) transgenic mice_Tg276 strainJackson LaboratoryJAX: 004919**Oligonucleotides**CpG 2006MicrosynthN/A**Recombinant DNA**Plasmid: IgG1 expression vector[@bib86]PMID:17996249Plasmid: Igk expression vector[@bib86]PMID:17996249pMX-YU2-ENVΔCT- IRES-GFPProvided by Dr. Hugo Mouquet, PasteurN/APlasmid: MPER-TM2 expression vectorThis studyN/A**Software and Algorithms**Prism 8GraphPad<https://www.graphpad.com/scientific-software/prism/>CLC Main Workbench 8QIAGEN<https://www.qiagenbioinformatics.com/products/clc-main-workbench/>IMGT-the International Immunogenetics Information SystemLefranc et al., 1999<http://www.imgt.org>XDS[@bib42]PMID:20124693Phaser[@bib56]PMID:19461840COOT[@bib24]PMID:20383002REFMAC[@bib65]PMID:15299926Phenix[@bib1]PMID:20124702SBGrid[@bib61]N/APymolWarren DeLano[www.pymol.org](http://www.pymol.org){#intref0055}VMD (Version 1.9.4)[@bib35]<https://www.ks.uiuc.edu/Research/vmd/>NAMD (Version 2.13)[@bib70]<https://www.ks.uiuc.edu/Research/namd/>CHARMM-GUI[@bib39]<http://www.charmm-gui.org>WebLogo[@bib80]<https://weblogo.berkeley.edu/logo.cgi>wwPDB OneDep System<https://deposit-pdbe.wwpdb.org>wwPDB Validation Service<https://validate.wwpdb.org/>BLI Data Analysis software (v11.1.0.25)Pall FortéBio<https://www.moleculardevices.com>SBGrid Consortium([@bib61])<https://sbgrid.org/>Python 3.7<https://python.org>Biacore T200 Control Software<https://www.gelifesciences.com/biacore>

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Plasmids and mAbs generated in this study will be made available on request but may require a payment and/or a completed Material Transfer agreement if there is potential for commercial application. Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Winfried Weissenhorn (<winfried.weissenhorn@ibs.fr>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cell Lines {#sec4.3.1}

TZM-bl wild-type and TZM-bl expressing the FcγRI cells were obtained from NIH-AIDS Research and Reference Reagent Program (ARRRP) and used for neutralisation assays. TZM-bl wild type cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 units of Penicillin and 0.1 mg/ml of Streptomycin while TZM-bl expressing the FcγRI cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 0.025M Hepes, 50 μg/ml of Gentamicin, 20 μg/ml of Blasticidin. Both cell lines were cultivated at 37°C in a humidified 5% CO~2~ incubator. Cell monolayers were split at 1x10^6^ cells/T175 flask at confluence by treatment with 0.25% trypsin. Raji-Env cells (obtained from the ATCC, ATCC® CCL-86™) were cultured in RPMI supplemented with 10% FCS and 1% penicillin/streptomycin at 37°C in 5% CO2 and were used for CDC experiments. Expi293F cells (ThermoFisher Scientific) were maintained in Expi293 Expression Medium and cultivated at 37°C in a humidified 8% CO~2~ incubator (shaker with 25-mm shaking diameter, speed set to 140 rpm). Cells were split, once they reached a density of approximately 1-4x10^6^ cells/ml, at 0.3x10^6^ cells/ml. Expi293F cells were used for Ab production. The sex of all cell lines is female.

### HIV-1 Primary Viruses {#sec4.3.2}

NLAD8, YU2 and transmitted-founder HIV-1 strains (CH058, CH077; obtained from the NIH AIDS Reagent Program) were prepared by the transfection of 293T cells (obtained from the ATCC) along with vesicular stomatitis virus G (VSV-G) to normalize infectivity, as done previously ([@bib11]). HIV-1 PVs were provided by the Fraunhofer Institute for Biomedical Engineering IBMT.

### Sample Collection {#sec4.3.3}

Male donor SA003 (year of birth 1963), ART naïve, was selected among a cohort of HIV-1-infected patients enrolled in the Hospital "Sacco" in Milan due to the ability of its plasma to neutralize eight out of nine HIV-1 PVs of the Global Panels. The aforementioned donor is a Long Term Non-Progressor (LTNP) patient who consented to lymphadenectomy, signed informed written consent and underwent surgery. At that time, he had been infected with HIV-1 for 30 years with CD4 T-cell counts of 474 cells/μl and plasma HIV-1 RNA values of 1600 copies/ml, CDC stage A1. The donor was not involved in previous procedures and he had never received antiretroviral therapy. The protocol was approved by the Ethic Commission Milan Area A (Comitato Etico Interaziendale Milano Area A) protocol Number 0006143 on February 20^th^ 2015.

### Animals {#sec4.3.4}

Treatment-naive female, 6-10 weeks old, homozygous human FcRn (huFcRn) transgenic mice (Tg276 strain, Jackson Laboratory Bar Harbor, ME) were used to assess the pharmacokinetics of monoclonal antibodies. Mice were bred in the specific pathogen-free (spf) facility at the Institute for Research in Biomedicine Switzzerland under a chow diet. All the *in vivo* procedures were performed in accordance with the Swiss Federal Veterinary Office guidelines and as authorized by the Cantonal Veterinary Office.

Methods Details {#sec4.4}
---------------

### B-cell Isolation and Stimulation {#sec4.4.1}

Memory and GC B cells from patient SA003 were isolated from cryopreserved lympho node mononuclear cells (LNMCs) as follows: LNMCs were stained with anti-human CD19 PE-Cy7 (BD Bioscience_341113), anti-human IgM FITC (Invitrogen_A21215), anti-human IgA FITC (Invitrogen_A18788), anti-human CD27 BV650 (Biolegend_302827), anti-human CD38 APC (Beckman Coulter_555462) and anti-human CD14 PC5 (Beckman Coulter_A07765) plus anti-human CD3 PC5 (Beckman Coulter_A07749) on ice for 20 min. The cells were then washed, filtered and sorted using FACSAria (Becton Dickinson). Memory IgG^+^ B cells were sorted as CD19^+^CD27^+^CD38^-^ while GC IgG^+^ B cells as CD19^+^CD27^+^CD38^+^, both negative for all other markers, resuspended in complete IMDM with 10% FBS and immortalized with Epstein-Barr virus (EBV) in the presence of 2.5 μg/ml CpG 2006, 2.5 μg/ml AffiniPure F(ab')~2~ Fragment Goat Anti-Human IgA+IgG+IgM (H+L) (Jackson Immunoresearch), 500 U/ml IL-2, 5 ng/ml IL-6 (BD Pharmingen) and 10 ng/ml IL-21 (ImmunoTolls). The two subsets of B cells were seeded at 0.5 cells per well on a monolayer of Mesenchimal Stromal Cells (MSC) (Corti et al., 2014; Pinto et al., 2013) in 384-well microtiter plates. After 2 weeks, the supernatants were screened for neutralization activity using high throughput micro-neutralization assay against BJOX and CE1176 HIV-1 PVs. The B-cell cultures that neutralized both the PVs were then re-tested in secondary screening against the same PVs plus other two: X1632 and 25710. The B cells that neutralized four out of four HIV-1 PVs were lysed and the variable regions of the heavy and light chain were cloned.

### Sequence Analysis of Antibody cDNA {#sec4.4.2}

cDNA was synthesized from selected B-cell culture and both the heavy and light chain variable regions (VH and VL) were sequenced as previously described ([@bib86]). Using the Database: IMGT (<http://www.imgt.org>), the VH and VL gene family and the number of somatic mutations were determined by analyzing the homology of the VH and VL sequences to known human V, D and J genes. UCA sequences of the VH and VL were constructed using IMGT/V-QUEST.

### Production of Recombinant Antibody and Antibody Variants {#sec4.4.3}

The variable regions of the heavy and light chain were cloned into IgG1 and IgΚ expression vectors ([@bib86]) and expressed recombinantly by transient transfection of Expi293F cells (ThermoFisher Scientific) using polyethylenimine (PEI). After 7 days, cell culture supernatants were collected, centrifuged, filtered and purified by protein A chromatography (GE Healthcare). The purified antibodies were quantified using Pierce Rapid Gold BCA Protein Assay kit (ThermoFisher Scientific).

### Neutralization Assays {#sec4.4.4}

A single-cycle infectivity assay was used to measure the neutralization of luciferase-encoding virions pseudotyped with the desired HIV-1 Env-protein. For the primary screening, the culture supernatants from day 14 were tested using 384-well based HIV-1 PVs microneutralization assay using in parallel two strains, CE1176 and BJOX2000 representative respectively of clade C and CRF07. Neutralization were undertaken on TZM-bl (3000 cell per well). Briefly, 10μl of culture supernatant was pre-incubated with 10 μl of diluted HIV-1 PVs for 1h at 37° (5% CO~2~) and then added on the top of TZM-bl. After an incubation of 72h at 37°, the cells were lysed with BriteLite reagent (PerkinElmer) and the luciferase activity detected using the EnVision multimode plate reader (PerkinElmer). For the secondary screening, the neutralization was performed following the same protocol but making four dilution of the culture supernatant before adding the HIV-1 PVs (CE1176, BJOX2000, X1632 and 25710). To test the breadth and potency of the recombinant antibodies, the neutralization assay was performed in 96-well plates. Briefly, 35μl of serial diluted mAb were pre-incubated with 35μl of HIV-1 PVs for 1h at 37° and then added on TZM-bl or TZM-bl expressing FcγRI, depending on the experiment, seeded the day before at 10 000 cell per well. The volume of medium was then adjusted to 200 μl per well the day after. After an incubation of 72h at 37°, the cells were lysed, and the luciferase activity measured using the EnVision. IC~50~ and IC~80~ were calculated by nonlinear regression analysis using the GraphPad Prism 5 software.

Neutralization against the extended panel of HIV-1 PVs ([@bib34]) was employed to evaluate breadth and potency. Neutralization was assessed after a single round of infection in either TZM-bl or TZM-bl/FcγR1 cells using non-reported PV as described ([@bib59]). A pre-titrated dose of PV was incubated with serial 3-fold dilutions of test sample in duplicate in a total volume of 150 μl for 1 hr at 37°C in 96-well flat-bottom culture plates. Freshly trypsinized cells (10,000 cells in 100 μl of growth medium containing 75 μg/ml DEAE dextran) were added to each well. One set of 8 control wells received cells + virus (virus control) and another set received cells only (background control). After 48 hours of incubation, 100 μl of cells was transferred to a 96-well black solid plate (Costar) for measurements of luminescence using the Britelite Luminescence Reporter Gene Assay System (PerkinElmer Life Sciences). Assay stocks of PV were prepared by transfection in 293T/17 cells (American Type Culture Collection) and titrated in TZM-bl cells as described ([@bib59]).

### ADCC Assay {#sec4.4.5}

HIV-1-infected target CEM-NKR.CCR5 CD4 T cells were stained using the Far Red DDAO cell tracker (Life Technologies). 2--5 ×10^4^ target cells were plated in U-bottom 96-well plates and incubated with antibodies (15 μg/ml) for 5 min at room temperature. NK cells were added in each well (at a ratio of 1 CEM-NKR-CCR5 : 10 NK). Plates were spun 1 min at 300 g to promote cell contacts and incubated at 37°C for 4 h. Cells were then stained for intra-cellular Gag with the anti-Gag KC57 murine monoclonal antibody. To measure cell viability, the live/dead fixable aqua dead cell marker (1: 1,000 in PBS, Life Technologies) was added 20 min at 4°C before fixation. Data were acquired on a BD FACS CANTO II and analysed using FlowJo software. The frequencies of Gag+ cells among Far-Red+ cells were determined. ADCC was calculated using the following formula: 100 × (% of Gag+ target cells plus NK without antibody - % of Gag+ target cells plus effector with antibody)/(% of Gag+ target cells plus NK without antibody). Negative values were set to zero. Antibodies used in this assay, 3BNC117 ([@bib77]), 10-1074 ([@bib63]), PGT128 ([@bib92]), PGT151 ([@bib25]), 4E10 ([@bib85]), 10E8 ([@bib33]) and mGO53 ([@bib93]) were produced as described above.

### Complement-dependent Cytotoxicity Assay {#sec4.4.6}

Raji-Env cells were generated with Raji cells (obtained from the ATCC, ATCC® CCL-86™) that were spinoculated (1,000g for 1,5h at 32°C) with a retroviral viral vector carrying Env (pMX-YU2 ENVΔCT-GFP-PuroR) ([@bib71]). Transduced cells (GFP+) were sorted and cultivated in the presence of Puromycin (1μg/ml, Sigma). High level of Env expression was then obtained by subcloning. 0.5 x 105 Raji-Env Cells were cultivated in presence of 50% normal human serum (NHS) or heat-inactivated human serum (HIHS) and with or without antibodies (15 μg/ml). After 24h, cells were washed twice with PBS and stained with the live/dead fixable aqua dead cell marker (1:1,000 in PBS, Life Technologies) for 30 min. Cells were then fixed with 4% PFA for 10min at RT. The frequency of dead cells was measured by flow cytometry (Attune Nxt, ThermoFischer). CDC was calculated using the following formula: 100 x (% of dead cells with antibody - % of dead cells without antibody)/(100 - % of dead cells without antibody).

### Pharmacokinetic Analysis {#sec4.4.7}

LN01 pharmacokinetic was performed in Tg276 huFcRn transgenic mice in parallel with palivizumab and a control mAb specific for an irrelevant antigen. The mAbs were administered i.v. at 10 mg/ml (number of mice per group = 5). The concentration of human IgG mAbs in plasma were determined at multiple time points: 1-, 5-, 9-, 13- and 16-days post-administration. Mice bleeding was performed from the tail vein of mice.

### Autoreactivity Assays {#sec4.4.8}

The LN01 mAb autoreactivity was tested by indirect immunofluorescence on human HEp-2 cells and by ELISA against a self-antigen, the human cardiolipin. In the first approach, LN01 mAb was tested at 50 μg/ml on slides coated with HEp-2 cells in parallel to a negative control and the positive control provided by the kit as well as 4E10 and 10E8 at 50 μg/ml. All the procedure was performed according to the kit specifications (Zeus Scientific). In the second approach, the anti-cardiolipin ELISA was performed according to the kit instructions (GenBio). Serial dilutions of the mAbs were tested on the pre-coated 96-well plate.

### ELISA Assay {#sec4.4.9}

The binding of LN01, 10E8 and HK20 ([@bib76]) mAbs to the 28 amino acids long peptide encompassing the entire gp41 MPER was tested by ELISA using 96 well plates half-area. Briefly, ELISA plates were coated with 2 μg/ml of the long peptide (Pepscan), blocked with 1% BSA and incubated with titrated antibodies, followed by AP-conjugated anti-human IgG secondary antibody (SouthernBiotech). Plates were then washed and substrate (p-NPP, Sigma) was added. After 1h of incubation, plates were read at 405 nm. For human IgG quantification in the plasma of mice from *in vivo* experiment, 96 well plates were coated with 10 μg/ml of goat anti-human IgG UNL (SouthernBiotech), blocked with 1% BSA and incubated with titrated plasma, followed by AP-conjugated anti-human IgG secondary antibody (SouthernBiotech). Plates were then washed and substrate (p-NPP, Sigma) was added. After 30 min of incubation, plates were read at 405 nm. As standard to quantify human IgG concentration, serial dilutions of Rituximab were used.

### Linear Epitope Mapping {#sec4.4.10}

Linear epitope mapping was performed by peptide microarray as previously reported ([@bib29], [@bib82]). The peptides were printed onto 3D-Epoxy glass slides and were analyzed with a GenePix 4000B scanner ([@bib88]). The binding of LN01 and 7B2 was detected by incubation with DyLight 649-labeled goat anti-human IgG. Fluorescence intensity was measured using a GenePix 4000B scanner and was analyzed with GenePix software. Signal intensity is the median fluorescence intensity of triplicate spots for each peptide included on array slides.

### Gp41 Peptides {#sec4.4.11}

The MPER-TM1 peptide (671-NWFDITNWLWYIKLFIMIV-KKKKKK-689) was synthesized (Smart Bioscience, Grenoble). MPER-TM2 contains an N-terminal His-tag, a flag-tag a TEV protease site and gp41 residues 630 to 711 similar to the construct described before ([@bib54]). For crystallization, the construct was engineered to contain a second TEV protease site inserted at position 649, which produced gp41-TM2 containing residues 650 to 711. The cDNAs were cloned into petM20 and expressed in C41 *E. coli* cells for 3h at 37⁰. Cells were lysed by sonication in a buffer containing 20 mM Tris pH8.0, 100 mM NaCl, 1% CHAPS. The soluble fraction was passed over a Ni^2+^-chromatography column. Purified gp41 was cleaved by TEV protease at a ratio (w/w) 1:10 passed over an anion exchange column followed by a second Ni^2+^-chromatography column to remove non cleaved protein. The resulting MPER-TM2 was further purified by size exclusion chromatography on a S200 column in a buffer containing either 25 mM Hepes pH7.5, 150 mM NaCl, 3 mM Fos-Choline-12 or 25 mM Hepes pH7.5, 150 mM NaCl, 1% β-OG (n-Octyl-β-D-glucosid). For complex formation of MPER-TM2 with LN01 Fabs, the complex was purified by SEC on a superdex 200 column in a buffer containing 25 mM Hepes pH7.5, 150 mM NaCl, 3 mM Fos-Choline-12. The complex was concentrated to 10 mg/ml. For complex formation of the MPER-TM1 peptide with LN01 Fabs, the peptide was solubilized in a buffer containing 25 mM Hepes pH7.5, 150 mM NaCl, 6 mM Fos-Choline-12 at 2 mg/ml, mixed with LN01 Fabs in a buffer containing 25 mM Hepes pH7.5, 150 mM NaCl, 3 mM Fos-choline-12 and concentrated to 10 mg/ml. The peptide was added to the LN01 Fabs at the molar ratio of 1:1.5 (Fab : MPER-TM1 peptide).

### Surface Plasmon Resonance (SPR) Analysis {#sec4.4.12}

Biacore T200 (GE Healthcare, USA) was used for real-time binding interaction studies. Antibodies LN01 and 10E8 were immobilized via amine coupling on CM5 chips (GE Healthcare) in Hepes buffer (pH 7.5) at a flow rate of 10 μl/min until the surface plasmon resonance reached 2000 RU. Analyte concentrations varied from 1 to 2048 nM. Different dilutions of analytes were sequentially injected at a flow rate of 90 μl/min for 180s. MPER-TM1 and MPER-TM2 analytes were applied in a buffer containing 20 mM Tris pH 7.5, 100 mM NaCl, and either 1% β-OG (n-Octyl-β-D-glucosid) or 3 mM Fos-Choline-12. The dissociation time was set for 5 min and 0.1% SDS was injected for regeneration of the sensor chips. The sensogrammes were processed and visualized with Python. SPR profiles were fit to a double exponential equation. The model of biphasic binding was identified as the two state conformational change model, since the concentration dependencies of eigenvalues were linear. Dissociation constants were calculated as described ([@bib87]).

### Bio-layer Interferometry Binding Analysis {#sec4.4.13}

Binding measurements between LN01, LN01 variants and MPER-TM2 were carried out on an Octet Red instrument (ForteBio). For the determination of the binding between LN01 IgG and MPER-TM2, LN01 IgG were labelled with biotin (EZ-Link NHS-PEG4-Biotin) and bound to Streptavidin (SA) biosensors (ForteBio). The biosensors loaded with IgG were equilibrated in the kinetic buffer (25 mM HEPES pH 7.5, 150 mM NaCl and 0.1 % Fos-Choline-12) for 120 sec prior to measuring association with MPER-TM2 for 200 seconds at 25°C. Data were analyzed using the ForteBio analysis software version 11.1.0.25 (ForteBio). For LN01 sH/sL, LN01 gH/sL and LN01 sH/gL-FR the kinetic parameters were calculated using a global fit 1:1 model. For the determination of the binding of LN01 sH/sL, LN01 gH/gL and LN01 gH/UCA, K~D~ were estimated by steady state analysis. For LN01 UCA/sL, LN01 UCA/gL and LN01 UCA/UCA no binding was detected in this experimental setup. All bio-layer interferometry experiments were conducted at least three times.

### Crystallization, Data Collection and Structure Determination {#sec4.4.14}

Crystal screening was performed at the High Throughput Crystallisation Laboratory (HTX lab, EMBL Grenoble) in 96-well sitting drop vapour diffusion plates (Greiner). Following optimization, crystals used for diffraction studies were grown at 20°C (293 K) in hanging drop vapour diffusion plates. The LN01/MPER-TM1 complex was crystallized in 0.1 M HEPES pH 7.5, 10 %(w/v) PEG 3350. Crystal were grown by mixing 1 μl of the reservoir containing 0.1 M HEPES pH 7.5, 10 %(w/v) PEG 3350, 0.1%(w/v) Fos-Choline-12 and 1 μl of protein at a concentration of 8 mg/ml. The crystal was soaked into a cryo protectant solution containing 0.1 M HEPES pH 7.5, 5 % (w/v) PEG 3350, 30 %(w/v) Ethylene glycol, 0.1 %(w/v) Fos-Choline-12, and flash cooled in liquid N2 at 100 K. For LN01/MPER-TM1, data were collected on the ESRF beamline ID30A at a wavelength of 0.9677 Å. Data were processed with the program XDS ([@bib42]). The LN01/MPER-TM1 crystals belong to space group P 4~3~ 2~1~ 2 ([Table S2](#mmc1){ref-type="supplementary-material"}) and the structure was solved by molecular replacement using the program Phaser ([@bib56]) and a model of the LN01 Fab generated by I-Tasser ([@bib96]). The model was rebuilt using COOT ([@bib24]) and refined using REFMAC ([@bib65]) and Phenix ([@bib1]). Statistics for data reduction and structure refinement are presented in [Table S2](#mmc1){ref-type="supplementary-material"}.

The crystals of LN01/MPER-TM1 plus 1,2-dihexanoyl-sn-glycero-3-phospho-L-serine (06:0 PS) were obtained by adding 1 mM of 06:0 PS in the protein solution and in the cryoprotectant solution. X-ray data were collected on the ESRF beamline ID23eh1, at a wavelength of 0.98 Å and data were processed with the program XDS ([@bib42]).

The LN01/MPER-TM2 complex was crystallized by mixing 1 μl of 10 mg ml-1 of the LN01/MPER-TM2 complex and 1 μl of the reservoir solution containing 0.1 M HEPES pH 7.5, 9 %(w/v) PEG 8000, 8% Ethylene glycol, 10 mM MnCl~2~. For cryo protection, crystals were soaked in 0.1 M HEPES pH 7.5, 9 %(w/v) PEG 8000, 25 %(w/v) Ethylene glycol, 10 mM MnCl~2~, 0.1 %(w/v) Fos-Choline-12 prior to flash cooling in liquid N2 at 100 K. X-ray data were collected on the ESRF beamline ID30B at a wavelength of 0.9763 Å and data were processed with the program XDS ([@bib42]). The LN01/MPER-TM2 crystals belong to space group P 2~1~ 2~1~ 2~1~ ([Table S2](#mmc1){ref-type="supplementary-material"}). The structure was solved by molecular replacement using the program Phaser ([@bib56]) and the LN01/MPER-TM1 model coordinates. The model was rebuilt using COOT ([@bib24]) and refined using REFMAC ([@bib65]) and Phenix ([@bib1]). Statistics for data reduction and structure refinement are presented in [Table S2](#mmc1){ref-type="supplementary-material"}. The models were evaluated by using COOT and Phenix validation tools.

Two copies of the LN01/MPER-TM1 complex and 4 copies of the LN01/MPER-TM2 complex are present in the asymmetric units of the respective crystals. Numbering of the Fab was performed according to Kabat. The LN01/MPER-TM1 complex was refined to 3.2 Å data with an R/Rfree of 21.3/25.3%. 96.22% of the residues are within the most favoured regions of a Ramachandran plot. The LN01/MPER-TM1 + 06:0 PS complex was refined to 3.1 Å data with an R/Rfree of 23.8/26.7%. 95.8% of the residues are within the most favoured of a Ramachandran plot. The LN01/MPER-TM2 complex was refined to 3.9 Å data with an R/Rfree of 21.8/26.0% and 95.39% of the residues are within the most favoured regions of a Ramachandran plot. ([Table S2](#mmc1){ref-type="supplementary-material"}). Some of the software packages used in this study were compiled by SBGrid ([@bib61]).

### Figure Generation {#sec4.4.15}

Molecular graphics figures were generated with PyMOL (W. Delano; The PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC, <http://www.pymol.org>). To determine the angle of approach of antibodies LN01, 10E8, 4E10 and DH511.1 to gp41 MPER a similar method as described ([@bib95]) was employed. Briefly, an axis was drawn from a spatial position midway between the variable region disulfide bond to the Cα atom of residue T676 thereby defining the direction of approach. The representation of the sequence conservation of MPER shown in [Figure S6](#mmc1){ref-type="supplementary-material"} was generated using WebLogo ([@bib80]).

### Molecular Dynamics (MD) Simulation {#sec4.4.16}

The molecular assay consisted of gp41 MPER-TM2 or only TM embedded in a lipid bilayer formed by 20 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC), 44 1-palmitoyl-2-oleoyl-phosphatidylethanolamine (POPE), 18 1-palmitoyl-2-oleoyl-phosphatidyl serine (POPS), 28 sphingomyelin d18:0/d16:0 (SSM) and 90 cholesterol units in equilibrium with 11,123 water molecules, corresponding to a cell dimension of approximately 66 × 66 × 120 Å^3^. K^+^ and Cl^-^ ions were added to reach an ionic concentration of 150 mM. All molecular dynamics (MD) simulations reported herein were performed employing the parallel, scalable program NAMD 2.12 ([@bib70]). Periodic boundary conditions (PBCs) were applied in the three directions of Cartesian space. Water was described by the TIP3P model ([@bib40]), and both gp41 and its lipid environment by the all-atom CHARMM36 force field ([@bib39], [@bib43], [@bib55]). A mass repartitioning scheme was introduced, allowing the equations of motion to be integrated with a time step of 4 fs, using the r-RESPA multiple time-step algorithm ([@bib90]). Covalent bonds involving hydrogen atoms were constrained to their equilibrium length by means of the RATTLE ([@bib4]) and SETTLE algorithms ([@bib57]). The temperature and the pressure were maintained at 303 K and 1 atm, respectively, using Langevin dynamics and the Langevin piston method ([@bib26]). Long-range electrostatic forces were taken into account by means of the particle mesh Ewald algorithm ([@bib20]). A 12-Å cutoff was applied to truncate van der Waals and short-range Coulombic interactions. Visualization and analyses of the MD trajectories were performed with the VMD program ([@bib35]). The free-energy landscape underlying the transition of gp41 from its straight to its bent form was determined using a multiple-walker version ([@bib19]) of the MW-ABF algorithm ([@bib18]) with a reaction coordinate model equal to the difference of the distance root mean square deviations (RMSD) with respect to these two conformations and eight walkers. No assumption was made on the initial orientation of the MPER-TM2 segment. The latter was placed such that its longitudinal axis was aligned with the normal to the lipid bilayer, i.e., the *z*-axis of Cartesian space. Next, the computational assay was suitably thermalized until a plateau in the dimensions of the membrane patch was reached and a steady orientation of the MPER-TM2 segment was observed. The tilt angle reported in this work is, therefore, a consequence of the sequence of the MPER-TM2 segment in relationship with the composition of the lipid bilayer, rather than an initial placement suggested by experiment. The steady orientation of the MPER-TM1 segment served as a starting point for the LN01-MPER-TM2 simulation.

The initial gp41 MPER-TM2 assay was built by aligning gp41 onto its equilibrium conformation sampled from the simulation with the isolated straight TM peptide. Lipids and water molecules were thermalized during 50 ns, while maintaining atoms of the protein complex to their crystallographic positions by means of harmonic restraints. Next, a set of three harmonic restraints over root-mean-square deviation collective variables was used to maintain backbones of LN01 and MPER-TM2 and side chains of LN01/MPER-TM2 contact residues in their reference conformation, respectively. Using this protocol, the orientation of the protein complex with respect to the bilayer was equilibrated during 200 ns. Finally, all the restraints were removed, and a 200 ns trajectory was produced.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Antidody EC50 and EC80 and serum ID50 were determined from log-transformed nonlinear regression, dose-response sigmoidal curve fit data using GraphPad 8. Antibody neutralization values higher then 12.5 or 25 μg/ml were considered as negative. The results were reported in [Figures 1](#fig1){ref-type="fig"}E and [2](#fig2){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}. Statistical models inherent to REFMAC ([@bib65]) and Phenix ([@bib1]) were employed for the structure refinement. All binding and neutralization assays were conducted with at least duplicate measurements. ADCC responses were analyzed in the Wilcoxon test. The results were reported in [Figure 3](#fig3){ref-type="fig"}C.

Data and Code Availability {#sec4.6}
--------------------------

All data generated or analyzed during this study are included in this published article (and its [Supplemental Information](#mmc1){ref-type="supplementary-material"}). Atomic coordinates and structure factors of the reported crystal structures have been deposited in the Protein Data Bank (<https://www.rcsb.org>; PDB: [6SNC](pdb:6SNC){#intref0125}, [6SND](pdb:6SND){#intref0130}, [6SNE](pdb:6SNE){#intref0135}).
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